Elham Shakerian
Overview
Explore the profile of Elham Shakerian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dinarvand N, Afarin R, Shakerian E, Salehipour Bavarsad S, Mohammadtaghvaei N
Mol Biol Rep
. 2024 Apr;
51(1):541.
PMID: 38642208
Background And Purpose: Liver fibrosis is a reversible liver injury that occurs as a result of many chronic inflammatory diseases and can lead to cirrhosis, which is irreversible and fatal....
2.
Asadizade S, Hatami M, Salehipour Bavarsad S, Kabizade B, Shakerian E, Rashidi M
Iran Biomed J
. 2024 Mar;
28(1):31-7.
PMID: 38468370
Background: Liver fibrosis, associated with hepatic stellate cells (HSCs), occurs when a healthy liver sustains damage, thereby impairing its function. NADPH oxidases (NOXs), specifically isoforms 1, 2, and 4, play...
3.
Afarin R, Dinarvand N, Jaberian Asl B, Orak G, Shakerian E, Bineshfar F, et al.
Iran J Basic Med Sci
. 2024 Jan;
27(2):241-246.
PMID: 38234671
Objectives: Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder in the world, with a global prevalence of 25%. Compounds with anti-inflammatory, lipid-lowering, and insulin-sensitizing properties can...
4.
Afarin R, Aslani F, Asadizade S, Jaberian Asl B, Mohammadi Gahrooie M, Shakerian E, et al.
Iran J Pharm Res
. 2023 Dec;
22(1):e134807.
PMID: 38116551
Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are 2 common liver diseases that currently lack effective treatment options. Objectives: This study aimed to investigate the effect of...
5.
Rashidi M, Matour E, Beheshti Nasab H, Cheraghzadeh M, Shakerian E
Iran Biomed J
. 2023 Aug;
27(4):199-204.
PMID: 37598299
Background: Currently, liver fibrosis is growing worldwide; unfortunately, there is no definite cure for this disease. Hence, understanding the molecular pathways involved in the development of liver fibrosis can help...
6.
Rashidi M, Matour E, Monjezi S, Asadi Zadeh S, Shakerian E, Sabahy S, et al.
Iran J Basic Med Sci
. 2023 Jun;
26(6):695-700.
PMID: 37275763
Objectives: Free cholesterol in the diet can cause liver fibrosis by accumulating in Hepatic stellate cells (HSCs). The rate of mortality of this disease is high worldwide and there is...
7.
Afarin R, Behdarvand T, Shakerian E, Salehipour Bavarsad S, Rashidi M
Iran J Basic Med Sci
. 2022 Dec;
25(12):1498-1503.
PMID: 36544529
Objectives: Activated cells which are called star-shaped cells, are some of the key factors in the development of liver fibrosis. Activation of NADPH oxidase (NOX) is associated with increased HSCs...
8.
Mohammadzadeh G, Afarin R, Salehipour Bavarsad S, Aslani F, Asadi Zadeh S, Shakerian E
J Diabetes Metab Disord
. 2022 Nov;
21(2):1531-1538.
PMID: 36404864
Background: In hepatic damage, Hepatic stellate cells (HSCs) become active, proliferate, and change to myofibroblasts. Increasing the fibrogenic genes, such as Transforming growth factor-β (TGF-β), Alpha Smooth Muscle Actin (α-SMA),...
9.
Shakerian E, Afarin R, Akbari R, Mohammadtaghvaei N
Mol Biol Rep
. 2022 Jan;
49(4):2839-2845.
PMID: 35067813
Background: Hepatic fibrosis is one of the main reasons for mortality in the world. Hepatic stellate cells (HSCs) activate during chronic liver injury, express more Transforming growth factor beta (TGF-β),...